United States-based Bon Secours Mercy Health, a Catholic health care system, has collaborated with United States-based Lirio LLC, a behavioural engagement solution, it was reported yesterday.
The strategic partnership was announced at the 38th annual JP Morgan Healthcare Conference and was initiated by a direct investment from Bon Secours Mercy Health in Lirio's behaviour change AI platform. John Starcher, president and CEO of Bon Secours Mercy Health will join Lirio's board of directors.
Both firms will co-develop new behaviour change programs that influence health decision-making for those at risk for chronic diseases, such as diabetes and hypertension. These programs will gradually be marketed and sold to other health systems globally under commercial terms agreed to between both parties. Bon Secours Mercy Health will license and install present Lirio behaviour change programs, such as women's health programs and programs that encourage the use of digital engagement tools like patient portals.
Ocular Therapeutix prices USD475m common stock offering
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Nanomi BV to acquire ophthalmology specialist VISUfarma BV
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth